Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis

Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis

Abstract Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe AD. In Italy, lebrikizumab has been a...

Full description

Saved in:
Bibliographic Details
Main Authors: Ippazio Cosimo Antonazzo, Giampiero Girolomoni, Cataldo Patruno, Roberto Langella, Veronica Ottobrino, Lorenzo Giovanni Mantovani, Paolo Angelo Cortesi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Dermatology and Therapy
Subjects:
Lebrikizumab
Budget impact analysis
Severe atopic dermatitis
Italy
Pharmacoeconomics
Online Access:https://doi.org/10.1007/s13555-025-01475-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01475-2

Similar Items